Skip to main content

Table 3 Factors associated with immunovirological discordance at 12 months on antiretroviral therapy at univariate and multivariate logistic regression

From: Immunovirological discordance among female sex workers who start antiretroviral therapy in Burkina Faso

Variable n (%) of immunovirological discordance Odds Ratio
(95% CI)
P Adjusted Odds Ratio
(95% CI)
P
Age (years)    0.3540   0.5032
 < 30 4 (16.00) 1   1  
 30–39 15 (60.00) 1.83 (0,54–6.20)   1.55 (0.39–6.10) 0.5323
 ≥ 40 6 (24.00) 1.97 (0.47–8.16)   1.76 (0.33–9.28) 0.5050
Marital status (couple life)    0.4166   
 No 4 (16.00) 1    
 Yes 21 (8400) 0.61 (0.19–2.00)    
BMI Class    0.3658   
 < 18,5 6 (24.00) 1    
 18,5–25 15 (60.00) 1.06 (0.36–3.08)    
 > 25 4 (16.00) 2.44 (0.52–11.56)    
WHO clinical stage    0.8640   0.5306
 1 3 (12.00) 1   1  
 2 8 (32.00) 0.99 (0.22–4.48)   0.82 (0.13–4.98) 0.8300
 3 and 4 14 (56.00) 1.08 (0.26–4.51)   1.28 (0.24–6.65) 0.7716
CD4 + T cell count (cells/µl)    0.0001   0.0012
 < 200 11 (44.00) 1   1  
 200–349 7 (28.00) 3.50 (1.13–10.83)   4.15 (1.13–15.22) 0.0317
 350–500 7 (28.00) 21.00 (3.85–114.51)   17.50 (2.68–114.31) 0.0028
ART NNRTIs initiated    0.4313   
 Nevirapine 5 (20.00) 1    
 Efavirenz 20 (80.00) 1.89 (0.63–5.61)    
 Protease inhibitor     
ART NRTIs initiated    0.0170   0.1800
 Tenofovir 6 (24.00) 1   1  
 Zidovudine 17 (68.00) 0.54 (0.16–1.75)   1.19 (0.27–5.29) 0.8177
 Stavudine 2 (8.00) 0.12 (0.02–0.74)   0.28 (0.04–2.11) 0.2183
ART Adherence    0.2495   
 < 95% 6 (24) 1    
 ≥ 95% 19 (76) 2.00 (0.72–5.56)